AF
RXDX

Amalgamated Financial’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Amalgamated Financial’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$143K Buy
+3,782
New +$149K ﹤0.01% 2021

Other funds holding RXDX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Financial's RXDX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Prometheus Biosciences, Inc. Common Stock (RXDX) in Q1 2022: 3,782 shares worth $143K. The stake represents ﹤0.01% of the portfolio and ranks #2021 among its holdings.

103 funds tracked by Wall St. Rank hold RXDX as of Q1 2022.

  • Amalgamated Financial held 3,782 shares of Prometheus Biosciences, Inc. Common Stock worth $143K as of Q1 2022.
  • Prometheus Biosciences, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
  • Prometheus Biosciences, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2021 holding.
  • 103 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.